IMGN - ImmunoGen, Inc.
| Previous Close | 5.83 |
| Open | 5.78 |
| Bid | 5.84 x 1200 |
| Ask | 6.01 x 4000 |
| Day's Range | 5.70 - 6.03 |
| 52 Week Range | 5.24 - 13.41 |
| Volume | 1,455,391 |
| Avg. Volume | 2,157,700 |
| Market Cap | 891.564M |
| Beta (3Y Monthly) | 3.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.24 |
| Earnings Date | Feb 7, 2019 - Feb 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
- Thomson Reuters StreetEvents•yesterday
Edited Transcript of IMGN earnings conference call or presentation 2-Nov-18 12:00pm GMT
Q3 2018 ImmunoGen Inc Earnings Call
- ACCESSWIRE•3 days ago
Healthcare Stocks with Turnaround Potential
HENDERSON, NV / ACCESSWIRE / November 14, 2018 / After a tough year, the prospect that a split congress could be a good thing for healthcare stocks is causing some investors to look again at several smaller ...
- Market Realist•6 days ago
How Has Cara Therapeutics’ 2018 Performance Shaken Out?
Cara Therapeutics (CARA) is a clinical-stage biotechnology company developing new chemical entities for managing pain and pruritus. Cara Therapeutics reported EPS of -$0.52 on revenue of $2.87 million in the second quarter.
- Motley Fool•8 days ago
ImmunoGen Waits to Leap "Forward"
Critical data from the Forward I trial is due out in the first half of next year.
- Motley Fool•10 days ago
Here's Why ImmunoGen Closed Almost 12% Up on Wednesday
An insider buy piques investors' interest.
- Motley Fool•10 days ago
Here's Why ImmunoGen Shares Lost 42.7% in October
Investors slowly backed away from the stock in anticipation of a big data release, which ended up landing with a thud later in the month.
- GlobeNewswire•11 days ago
Report: Developing Opportunities within TE Connectivity, EnPro Industries, Innophos, Ameren, ImmunoGen, and ICF International — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 07, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•11 days ago
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the following presentations by
- Simply Wall St.•12 days ago
How ImmunoGen Inc (NASDAQ:IMGN) Can Impact Your Portfolio Volatility
Anyone researching ImmunoGen Inc (NASDAQ:IMGN) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there are Read More...
- Zacks•12 days ago
ImmunoGen (IMGN) Beats on Earnings in Q3, Lowers Guidance
ImmunoGen (IMGN) reports narrower-than-expected loss in Q3. However, it misses estimates for revenues. Shares down.
Motley Fool•15 days agoImmunogen Inc (IMGN) Q3 2018 Earnings Conference Call Transcript
IMGN earnings call for the period ending September 30, 2018.
- Zacks•15 days ago
ImmunoGen (IMGN) Reports Q3 Loss, Lags Revenue Estimates
ImmunoGen (IMGN) delivered earnings and revenue surprises of 8.82% and -8.32%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•16 days ago
ImmunoGen: 3Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of 32 cents per share. Losses, adjusted for restructuring costs, came to 31 cents per share. The results surpassed Wall Street expectations. ...
- Business Wire•16 days ago
ImmunoGen Reports Recent Progress and Third Quarter 2018 Operating Results
Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine with KEYTRUDA® Reported at ESMO
- Benzinga•16 days ago
Q3 Earnings Outlook For ImmunoGen
ImmunoGen, Inc. (NASDAQ: IMGN ) announces its next round of earnings Friday. Here is Benzinga's everything-that-matters guide for the Q3 earnings announcement. Earnings and Revenue Analysts are predicting ...
- Business Wire•17 days ago
ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 60th ASH Annual Meeting
Phase 1 Data for IMGN779 and IMGN632 to be Highlighted in Oral Presentations at ASH
- Zacks•22 days ago
ImmunoGen (IMGN) Q3 Earnings Preview: What to Look Out For
ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool•26 days ago
Here's Why ImmunoGen Fell Today
Data presented at a medical conference weren't as good as investors were hoping for.
- Business Wire•29 days ago
ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 Congress
Preliminary Data Demonstrate Favorable Safety Profile and Encouraging Activity in Heavily Pretreated Patients with Ovarian Cancer
- Business Wire•last month
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2018 Operating Results
ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.m. ET on Friday, November 2, 2018 to discuss its third quarter operating results. The call may also be accessed through the Investors section of the Company’s website, www.immunogen.com. ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
- ACCESSWIRE•last month
Cancer Companies to Watch
HENDERSON, NV / ACCESSWIRE / October 15, 2018 / Below we've highlighted a few companies working on treatments for different types of cancers that could potentially create value for shareholders. One company ...
- Benzinga•last month
The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs
Here are a few catalysts that can dictate the directional moves of biotech stocks in the upcoming week: Conferences European Society For Medical Oncology, or ESMO, 2018 Congress – Oct. 19-23, in Munich, ...
- GlobeNewswire•last month
Report: Developing Opportunities within Southwest Airlines, Select Income REIT, Oxford Industries, ImmunoGen, Navigant Consulting, and TrueBlue — Future Expectations, Projections Moving into 2018
NEW YORK, Oct. 10, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•last month
ImmunoGen to Present Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO
ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that initial findings from the FORWARD II expansion cohort of mirvetuximab soravtansine in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), will be presented at the European Society for Medical Oncology (ESMO) Congress from October 19-23, 2018 in Munich, Germany. The poster will include initial safety and preliminary anti-tumor activity for 46 patients with platinum-resistant ovarian cancer (PROC), of whom 35 have medium or high folate receptor alpha (FRα) expression. Encouraging activity and favorable tolerability data from the FORWARD II dose-escalation cohort assessing mirvetuximab soravtansine in combination with KEYTRUDA in 14 heavily pre-treated patients with platinum-resistant epithelial ovarian cancer (EOC) were presented in March at the Society of Gynecologic Oncology (SGO) Annual Meeting.
Yahoo Finance Video•15 days agoMARKETS: Today's job numbers might have been too good and could spook stocks
Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Alexis Christoforous to discuss the latest market moves as Wall Street digests headlines about US-China trade relations, this morning's BLS Employment Situation report, and a barrage of earnings, from Apple to Exxon Mobil. Here's the performance of recent earnings (as of 10:45 am EDT, Friday): ~Thurs AMC SBUX Starbucks Corp 10.60% SYMC(E) Symantec Corp 6.43% MET Metlife Inc 4.41% X U.S. Steel Corporation 2.54% WU Western Union Co (THE) -0.25% CBS CBS Corporation -1.25% EOG EOG Resources -2.25% AAPL Apple Inc -6.72% KHC The Kraft Heinz Company -7.82% GERN(HB) Geron Corp -8.11% SHAK Shake Shack Inc -11.41% GPRO GoPro Inc Cl A -21.80% OLED Universal Display Corp -27.13% WTW Weight Watchers Intl -29.87% ~Fri BMO CVX Chevron Corporation 3.48% STX(HB) Seagate Tech 2.78% IMGN Immunogen Inc 2.69% ABBV AbbVie Inc 2.48% XOM Exxon Mobil 1.41% DUK Duke Energy Corporation 0.58% BABA Alibaba Group Holding Ltd -0.84% CBOE CBOE Glbl Mkts Inc -1.23%
